642097-79-8

Upstream product

• 145757-48-8 1-(1',3'-dioxyl-4',4',5',5'-tetramethyldihydroimidazol-2'-yl)-phenyl-4-yloxylacetic acid 
• 642097-77-6 1-(1',3'-dioxyl-4',4',5',5'-tetramethyldihydroimidazol-2'-yl)-phenyl-4-yloxylacetic ethyl ester 
• 152020-32-1 Boc-Arg(Tos)-Gly-Asp(OcHex)-Val-OBzl 
• 38577-52-5 1,3-dihydroxyl-2-(4'-hydroxyphen-1'-yl)-4,4,5,5-tetramethylimidazolidine 
• 14384-45-3 N,N'-dihydroxy-2,3-dimethylbutane-2,3-diamine 

Relevant academic research and scientific papers

Synthesis and bioactivities of nitronyl nitroxide and RGD containing pseudopeptides

1-(1′,3′-dioxyl-4′,4′,5′,5′- tetramethyldihydroimidazol-2′-yl)-phenyl-4-yloxylacetic acid (3), and 1-(1′,3′-dioxyl-4′,4′,5′,5′- tetramethyldihydroimidazol-2′-yl)-phenyl-4-yloxylacetyl-RGDS (13), -RGDV (14), -RGDF (15) were synthesized. The ESR measurement gave the same spectroscopy for 3 and 13-15. The NO scavenging tests in vitro, anti-platelet aggregation tests in vitro and the anti-thrombosis assay in vivo indicated that introducing 3 into the N-terminal of RGDS, RGDV and RGDF the corresponding bioactivities for both of 3 and RGD peptides can be remained completely. The present combinations provided a beneficial strategy for simultaneous scavenging NO and anti-thrombosis, and for the use of spin label of RGD peptides in the conformational researches.